Stem Cell Therapy Shows Promise for Fetal Spina Bifida Repair

A Phase I clinical trial published in The Lancet has demonstrated that combining stem cell therapy with standard fetal surgery is both safe and promising for treating myelomeningocele, a severe form of spina bifida. For the first time, surgeons utilized live stem cells directly on a fetus’s damaged spine, potentially improving outcomes beyond those achieved with conventional fetal surgery alone. Source

Understanding Spina Bifida and Current Limitations

Spina bifida is a congenital condition where the spinal cord doesn’t fully develop, leaving part of it exposed. This can lead to lifelong complications, including paralysis, difficulty walking, and bladder and bowel dysfunction. Source

While fetal surgery is currently performed to close the spinal opening during pregnancy, it doesn’t always prevent long-term neurological damage. This has driven researchers to explore innovative approaches to enhance nerve protection and recovery. Source

How the Stem Cell Procedure Works

In the trial, six pregnant women carrying fetuses diagnosed with myelomeningocele underwent standard fetal surgery. Surgeons then applied placenta-derived mesenchymal stem cells (PMSCs) directly onto the exposed spinal cord during the repair process. Source

These PMSCs, sourced from the placenta, are believed to reduce inflammation, promote tissue healing, and protect developing nerve cells. By delivering them directly to the site of injury, the surgical team aimed to strengthen spinal repair and improve neurological outcomes. Source

Encouraging Early Outcomes

The six babies, born between July 2021 and December 2022, demonstrated highly encouraging results. All spinal repairs remained intact at birth, and none of the infants developed infections, abnormal tissue growth, or tumor formation. Source

Post-birth MRI scans confirmed that hindbrain herniation—a brain abnormality often associated with spina bifida—reversed in every case. Researchers too observed no serious adverse effects linked to the stem cell therapy during the trial or subsequent follow-up. Source

Long-Term Monitoring Underway

Researchers will continue to monitor the children closely until they reach six years of age. Regular medical assessments will evaluate mobility, neurological development, overall health, and quality of life. This extended follow-up will help confirm the long-term safety and sustained benefits of the treatment. Source

Next Steps in Clinical Research

Larger and longer-term clinical trials are underway to refine surgical techniques and standardize treatment protocols. These studies aim to verify whether the therapy consistently improves birth outcomes, mobility, and long-term functioning. Regulatory authorities are working closely with investigators to ensure rigorous safety and effectiveness standards. Source

A Milestone in In-Utero Therapy

Researchers believe this breakthrough represents a significant milestone in the field of in-utero stem cell treatment for congenital disorders. If future trials confirm its benefits, the therapy could become a standard option for fetal repair of spina bifida. Source

This innovation offers renewed hope to families worldwide and may pave the way for applying stem cell techniques during fetal surgery to treat other birth defects. Source